Therapeutic potential of protein and adjuvant vaccinations on tumour growth

被引：55

作者：

Gérard, CM

Baudson, N

Kraemer, K

Bruck, C

Garçon, N

Paterson, Y

Pan, ZK

Pardoll, D

机构：

[1] SmithKline Beecham Biol, R&D, Preclin Immunol, B-1330 Rixensart, Belgium

[2] Johns Hopkins Univ, Dept Oncol, Baltimore, MD USA

[3] Univ Penn, Sch Med, Philadelphia, PA 19104 USA

来源：

VACCINE | 2001年 / 19卷 / 17-19期

关键词：

cancer immunotherapy; HPV E7 protein; adjuvants;

D O I：

10.1016/S0264-410X(00)00486-2

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Over 90% of cervical cancers are associated with HPV infection. the commonest being the HPV-16 subtype. Two early viral genes. E6 and 7, play major roles in the development and maintenance of the malignant phenotype. The vaccine potential of a recombinant HPV16 E7 protein was examined in two murine models of E7-expressing rumours. Formulations including the immunostimulants MPL and QS21 induced therapeutically active immune responses leading to regression of pre-established TC1 tumour lesions, associated with induction of IgG antibodies, lymphoproliferation and CTL. Our data provide a clear incentive to investigate the clinical application of this approach in cancer immunotherapy. (C) 2001 Elsevier Science Ltd. All rights reserved.

引用

页码：2583 / 2589

页数：7

共 24 条

[1] Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines [J].